期刊文献+

3.0T磁共振~1H波谱成像技术在乳腺良恶性病变诊断中的应用 被引量:2

Application of 1H-MRS in differentiating benign and malignant breast disease at 3T MRI
下载PDF
导出
摘要 目的:探讨磁共振波谱成像技术在乳腺良恶性病变中的诊断价值。方法:收集我院2013年6月至2015年12月间行乳腺DCE-MRI、DWI及磁共振波扫描检查并经手术和穿刺活检病理证实的乳腺病变患者45例MRI检查资料,分析磁共振1H波谱成像技术对乳腺良恶性病变诊断价值。结果:45例中乳腺恶性病变19例,乳腺良性病变26例,共有17个恶性病灶及1个良性病灶在3.22ppm时出现胆碱峰,25个良性病变及2个恶性病变未出现胆碱峰,恶性病变为小叶原位癌及浸润性小叶癌,乳腺恶性病变与良性病变的1H波谱成像3.22ppm时出现胆碱峰差异有统计学意义(Х~2=33.54,〈0.05)。结论:磁共振~1H波谱成像技术在乳腺良恶性病变诊断中具有一定的诊断价值。 Objective: To explore the diagnostic value of 1H MRI in differential benign and malignant breast disease. Methods: 45 patients with breast lesion from 2013 to 2015 performed MRI examination at 3.0T scanner. Numbers and features of the lesion were analyzed on axial FSE T1WI, axial and sagittal T2WI,DWI,DCE-MRI and MRS. Comparative analysis of 1H-MRS and pathology results was performed. Results: 45 lesions were confirmed by histopathology including 19 malignant tumors and 26 benign tumors. There was statistical significant difference of total choline-containing compounds between malignant tumors and benign tumors( X2=33.54, P〈0.05). Conclusion: The teeh level of MRS was a diagnosis valuable method of benign and malignant breast tumors.
出处 《农垦医学》 2016年第3期206-209,共4页 Journal of Nongken Medicine
基金 新疆生产建设兵团石河子市科技项目(2014YL07)
关键词 乳腺癌 磁共振成像 磁共振波谱 Breast cancer Magnetic resonance Imaging Magnetic resonance spectroscopy
  • 相关文献

参考文献8

  • 1姜蕾,杜湘珂,周诚,陈敏,周意明,纪立伟,孙非,申皓.利用^1H MRS进行在体乳腺癌中复合胆碱外参照法定量的研究[J].中国医学影像技术,2008,24(3):393-397. 被引量:10
  • 2旷连勤,张玉龙,程海云,徐琰,陈金华,张伟国,陈蓉.1H-MRS复合胆碱积分在乳腺良恶性病变鉴别诊断中的应用[J].中国医学影像技术,2014,30(10):1500-1504. 被引量:8
  • 3Begley JK1, Redpath TW, Bolan PJ, et al. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature[J]. Breast Cancer Res, 2012, 14(2): 207-217.
  • 4Stanwell P, Gluch L, Clark D, et al. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5T[J]. Eur Radiol, 2005, 15(5): 1037-1043.
  • 5Baek HM, Yu HJ, Chela J, et al. Quantitative correlation between tH MRS and dynamic contrast-enhanced MRI of human breast cancer [J]. Magn Reson Imaging, 2008, 26(4): 523-531.
  • 6Dorrius MD, Pijnappel RM, Jansen Van Der Weide MC, et al. Determination of choline concentration in breast lesions: quantitative multi-voxel proton MR spectroscopy as a promising noninvasive assessment tool to exclude benign lesions [J]. Radiology, 2011, 259(3): 695-703.
  • 7Dorrius MD, Pijnappel RM, Jansen Van Der Weide MC, et al. The added value of quantitative muhi-voxel MR spectroscopy in breast magnetic resonance imaging[J]. Eur Radlol, 2012, 22 (4): 915-922.
  • 8Suppiah S1, Rahmat K, Mohd-Shah MN, et al. Improved diagnostic accuracy in differentiating malignant and benign lesions using single-voxel proton MRS of the breast at 3T MRI[J]. Clin Radiol, 2013, 68(9): 502-510.

二级参考文献29

  • 1Roebuck JR, Cecil KM, Schnall MD, et al. Human breast lesions: characterization with proton MR spectroscopy. Radiology, 1998, 209( 1 ) : 269-275.
  • 2Huang W, Fisher PR, Dulaimy K, et al. Detection.of breast malignancy : diagnostic MR protocol for improved specificity. Radiology, 2004,232(2) : 585-591.
  • 3Yeung DKW, Cheung HS, Tse GMK. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology, 2001,220 ( 1 ) :40-46.
  • 4Stanwell P, Gluch L, Clark D, et al. Specificity of Choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1. 5T. Eur Radiol, 2005,15(5) :1037-1043.
  • 5Jacobs MA, Barker PB, Argani P, et al. Combined dynamic contrast enhanced breast MR and proton spctroscopic imaging: a feasibility study. J Magn Reson Imag, 2005,21(1) : 23-28.
  • 6Kvistad KA, Bakken U, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging, 1999,10(2) :159-164.
  • 7Glunde K, Ackerstaff E, Natarajan K, et al. Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med, 2002,48(5):819-825.
  • 8Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant ehemotherapy of locally advanced breast cancer : predicting response with in vivo 1H MR speetroseopy-a pilot study at 4T. Radiology, 2004 233(2) :424-431.
  • 9北京化学试剂公司.化学试剂目录分册.北京:北京工业大学出版社,1993:171.
  • 10Bakken IJ, Gribbestad IS, Singstad TE, et al. External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5Tesla. Magn Reson Med, 2001,46 ( 1 ) : 189-192.

共引文献15

同被引文献35

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部